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Purpose: To evaluate the feasibility and usefulness of imipenem/cilastatin sodium (IPM/CS) as an embolic agent for
intestinal bleeding from neoplasms.
Materials and methods: Seven patients who underwent 11 transarterial embolisations (TAEs) using IPM/CS as an
embolic material for duodenal or small/large intestinal tumour bleeding from January 2004 to December 2011 were
retrospectively evaluated. A mixture of IPM/CS and contrast medium was introduced through the microcatheter
positioned at the feeding artery to the tumour until extravasation disappeared or stasis of blood flow to the
tumour staining was observed.
Results: Haemostasis was obtained in all patients. Therefore, the technical success rate was 100%. Rebleeding was
observed in four patients. All of them underwent repeat TAE using IPM/CS, and haemostasis was obtained
successfully. No complication was identified following laboratory and clinical examinations. No haemorrhagic death
occurred. Haemorrhagic parameters, including blood haemoglobin and the amount of blood transfusion, improved
after TAE.
Conclusion: The safety, feasibility, and effectiveness of TAE using IPM/CS as an embolic material for intestinal
bleeding from neoplasms were suggested by this study. The mild embolic effect of IPM/CS may be adequate for
oozing from tumours. Although rebleeding may occur after embolotherapy using IPM/CS, repeat embolisation is
effective as treatment for rebleeding.
Keywords: Bleeding; Neoplasm; Embolisation; IPM/CSIntroduction
Control of tumour bleeding is a compelling need for physi-
cians. Anticancer therapy, including resection, chemother-
apy, and radiation, can be a solution for bleeding from
neoplasms. Transcatheter arterial embolisation (TAE) may
be selected as rescue therapy for patients in whom haemo-
stasis is not achievable with these treatments.
Various embolic materials including metallic coils, gel-
atin sponges, n-butyl 2-cyanoac\rylate, polyvinyl alcohol* Correspondence: reikow@hotmail.co.jp
1Department of Diagnostic Radiology, Kitasato University School of Medicine,
1-15-1, Kitasato, Sagamihara, Minami-ku, Kanagawa 252-0374, Japan
Full list of author information is available at the end of the article
© 2013 Woodhams et al.; licensee Springer. Th
Commons Attribution License (http://creativeco
reproduction in any medium, provided the orig(PVA), and microspheres have been used for TAE for
intestinal bleeding (Kramer et al. 2000; Defreyne et al.
2001). When the bleeding origin vessel is well visualised
and superselectively accessible, coil embolisation will be
selected (Defreyne et al. 2001; Gordon et al. 1997;
Horiguchi et al. 2003; Ledermann et al. 1999). However,
it may be difficult to identify culprit vessels of tumour
bleeding on angiography because tumour bleeding is
likely to be attributed to fine vessels (Chuang et al.
1979). Additionally, tumour bleeding is sometimes inter-
mittent, and extravasation may not be observed at the
time of angiography. In these situations, superselective
embolisation using coils will not be feasible, and use ofis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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embolisation with these agents may cause ischaemic
complications of neighbouring intact structures, particu-
larly for small and large intestinal bleeding, because of
relatively poor collateral blood supply (Defreyne et al.
2001; Guy et al. 1992; Rosenkrantz et al. 1982). Pancrea-
titis and duodenal stricture have been reported as com-
plications after superselective TAE of the gastroduodenal
artery, mostly using glue and a gelatin sponge (Lang
1992; Loffroy & Guiu 2009).
In 1999, two Japanese studies reported introduction of
imipenem/cilastatin sodium (IPM/CS) as an embolic
agent for chemoembolisation in an animal model, in
which IPM/CS particles in a mixture with iodine con-
trast material were revealed as small in size, around 10
to 70 μm, and demonstrated a transient embolic effect
(Aihara 1999a; Aihara 1999b). Based on these character-
istics of IPM/CS, we assumed the usefulness of IPM/CS
as an embolic agent for intestinal bleeding from neo-
plasms. In clinical practice, we performed embolotherapy
using IPM/CS for patients who needed haemostasis for
bleeding from neoplasms, and who were poor candidates
for other therapeutic options such as endoscopic, surgical
haemostasis and embolotherapy with other embolic ma-
terials because of the possibility of ischemic complica-
tion. Arterial introduction of IPM/CS as a prophylactic
antibiotic for acute pancreatitis has been performed
(Buchler et al. 2000), indicating the safety of arterial
introduction of IPM/CS.
The purpose of the present study was to evaluate the
feasibility and usefulness of IPM/CS as an embolic
material for intestinal bleeding from neoplasms.
Materials and methods
Subjects
The Ethics Committee of Kitasato University Hospital
approved the present study
Indications for TAE were decided at angiography
based on active extravasation or tumour staining of the
known tumour. When TAE was indicated, a micro-
catheter was advanced into the artery whose blood supply
covered the area of extravasation as well as the area of
tumour staining.
Second, patients who bled from the duodenum or
small/ large intestine were chosen as candidates for use
of IPM/CS. Subsequently, the indication for IPM/CS was
determined when one of the following findings was ob-
served on the angiogram: 1) the bleeding artery was too
small to place the metallic coil; 2) extravasation was ob-
served, but the specific bleeding origin artery was hard
to detect; or 3) tumour staining, vascular encasement,
or vascular proliferation relating to the neoplasm was
observed, although no extravasation was observed. These
criteria were defined based on speculation that the size ofthe IPM/CS particle, mainly distributed from 10 to
70 μm (Aihara 1999a; Aihara 1999b), may be adequate
to embolise bleeding from small vessels. Patients who
showed unstable vital signs or were in shock were
excluded from the indication of IPM/CS.
Seven patients (five men and two women) underwent
11 TAE procedures using IPM/CS for duodenal or
small/large intestinal bleeding from neoplasms from
January 2004 to December 2011. Their ages ranged from
43 to 73 years (mean age: 59.2 ± 11.0 years). Four
patients had repeat TAE using IPM/CS.
All patients owned the neoplasm in the large or small
intestine at the time of intestinal bleeding”. The median
time from the onset of bleeding to angiography was
6 days, ranging from 0 to 20 days. The origins of bleed-
ing included invasion of pancreatic cancer to the duode-
num (n = 2), metastasis of renal cell carcinoma to the
pancreas invading to the duodenum (n = 1), invasion
of cervical cancer to the rectum (n = 1), colon cancer
(n = 1), and malignant lymphoma of the small intestine
(n = 2). No patient was a candidate for operative haemo-
stasis due to progression of the neoplasm (n = 6) or
pulmonary thromboembolism (n = 1) at the time of
bleeding. Four of seven patients had endoscopy before
angiography to attain haemostasis. Two of these four pa-
tients had rebleeding after endoscopic thermocoagulation.
In the other two patients, the endoscope could not reach
the bleeding sites because of narrowing of the intestinal
lumens caused by the tumours.Angiography
First, a 5 F introducer was placed in the right or left
femoral artery. Angiography of the celiac artery, superior
mesenteric artery (SMA), or inferior mesenteric artery
(IMA) was performed using a 5 F cobra or shepherd-
type catheter by injecting 20 to 25 ml of contrast medium
at a rate of 4.0 to 5.0 ml/sec for the SMA and celiac
artery and 10 ml to 15 ml at a rate of 2.0 to 2.5 ml/sec for
the IMA.Preparation and deployment of the IPM/CS mixture
A mixture of 0.5 g IPM/CS and 5 ml of contrast medium
was prepared for use as an embolic agent. Five millilitres
of contrast medium was put in a vial containing 0.5 g
IMP/CS and the mixture was stirred. The mixture was
then drawn into a 5-ml syringe and pumped gently with
a 2.5-ml syringe connected to the 5-ml syringe through
a three-way stopcock. This mixture was injected through
a microcatheter placed at the artery whose blood supply
covered the tumour staining until the extravasation
disappeared or stasis of blood flow to the tumour
staining was observed.
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The TAE procedure was deemed technically successful
when disappearance of extravasation or tumour staining
was attained at the time of the procedure.
All patients were carefully followed up with clinical
and laboratory examinations to check for rebleeding and
complications from embolisation for at least 1 week
at the hospital. Rebleeding was deemed positive when
melena, haematochezia, or haematemesis was observed.
Haematologic parameters, including the total number of
transfused units of packed red blood cells and averaged
haemoglobin for 7 days, were compared before and after
TAE to assess the effect of TAE.
Each patient was assessed for peritoneal signs and
symptoms such as tenderness, nausea, diarrhoea, fever,
and marked change in bowel sounds after embolisation
to determine the occurrence of ischaemic injury every
day for at least 1 week. Laboratory ischaemic evidence
was evaluated by assessing the increase in white blood
cell count (WBC), creatine phosphokinase (CPK), and
lactate dehydrogenase (LDH) by comparison of averaged
data of the patients for 7 days before and after TAE. In
evaluating the volume of blood transfusion, averaged
haemoglobin, WBC, CPK, and LDH for the two patients
who had repeat TAE within 24 hours after the first TAE
(patients 2 and 6), the data until the first TAE were
deemed the data before TAE, and data after the second
TAE were deemed the data after TAE. One patient
underwent upper gastrointestinal endoscopy after TAE
to explore haemostasis and to check for complications
(patient 3). Two patients were transferred to another
hospital to continue treatment for cancer after 44 and
339 days, respectively. The period of clinical follow-up
to check for rebleeding ranged from 37 to 339 days
after TAE (median, 163 days).Table 1 Summary of clinical course
Pt. no Age Sex Disease Outcome Proc
1 53 M Pancreatic cancer Died at day 247 1
2 59 M Malignat lymphoma Died at day 163 2
3
3 68 M Pancreatic lymphoma Died at day 48 4
5
4 73 M Pancreatic cancer Transferred at day 44 6
7
5 64 M Metastasis to the pancreas Died at day 224 8
6 46 F Invasion of cervical cancer
to the rectum
Transferred at day 339 9 1
7 43 F Colon cancer Died at day 37 11
Pt. no., patient number; Proc. no., procedure number; PA, pancreatic arcade; JA, jeju
SRA, superior rectum artery; LCA; left colic artery.Statistics
The Wilcoxon signed-rank test was used to compare
laboratory data and blood transfusion volume before and
after TAE using JMP 7.0 software (2007 SAS institute,
Inc., Cary, NC).
Results
A summary of the clinical course of the seven patients
(11 procedures) is shown in Table 1. Angiography revealed
tumour staining in all patients (Figure 1). Extravasation
was observed in three of the eleven procedures. However,
bleeding origin vessels accessible by microcatheter were
not found in any of the three procedures (Figure 1). All 11
procedures showed encased arteries, proliferation of blood
vessels, and prolonged staining with contrast enhancement
at locations of the known tumours, which were strongly
assumed to be origins of bleeding.
The positions of the microcatheter during embolisa-
tion were at the main trunk of the pancreatic arcade
(4 procedures), at a site proximal to the arterial arcade
of the jejunal artery (2 procedures), at a site proximal
to the arterial arcade of the ileal artery (2 procedures),
at a site proximal to the marginal artery of the left colic
artery (1 procedure), at the main trunk of superior rectal
artery (1 procedure), and at the main trunk of the inferior
rectal artery (1 procedure). Disappearance of extravasation
or blood flow to the tumour during the procedure was
obtained in all procedures. Thus, the technical success rate
was 100%. No complication was observed relating to the
TAE technique. The median amount of IPM/CS used for
TAE was 0.6 g (range: 0.2–1.5 g).
Bleeding recurred for five procedures (45%) in four
patients at 0, 0, 1, 10, and 21 days after TAE. TAE
was repeated after four of the five procedures and was
successful in all procedures. During all these repeatno. Extravasation Embolized artery IPM/CS (g) Rebleeding (day)
+ PA 0.5 -







0 IRA 0.4 0
SRA 0.4 -
+ LCA -
nal artery; IA, ileal artery; RCC, renal cell carcinoma; IRA, inferior rectum artery;
Figure 1 A 59-year-old man diagnosed with malignant
lymphoma at the jejunum had melena for 2 days (patient 2).
Angiography from the jejunal artery (a) showed extravasation of
the contrast medium (arrow). TAE with 0.2 g IPM/CS was
performed through a microcatheter placed at a site proximal to the
arterial arcade of the jejunal artery. Angiography post embolisation
(b) showed disappearance of extravasation and devascularisation
around the extravasation point (arrows). On the following day of the
first TAE, angiography was repeated because of haematemesis and
melena, which suggested rebleeding. Recanalisation of the jejunal
segment was observed without extravasation (c). Embolisation using
0.6 g IPM/CS was performed from the same site of the jejunal artery
as the first TAE. Haemostasis was successfully obtained and no clinical
or laboratory sign suggesting rebleeding was observed after the
second TAE. The patient died at 163 days after TAE because of the
progression of malignant lymphoma.
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embolised at the first TAE was observed (Figure 1c). For
the other patient suffering from rebleeding, haemostasis
occurred without repeat TAE. No conversion to surgical
haemostasis occurred.
The haematologic data are shown in Table 2. Trans-
fusion of packed red blood cells was performed for all
patients before TAE. After TAE, the volume of transfu-
sion of packed red blood cells was significantly reduced
(P = 0.0004). For six procedures, transfusion of blood cells
was not required for at least 7 days after TAE. The average
haemoglobin in 7 days increased after TAE, but no statisti-
cally significant difference was found (8.1 g/dl and 9.2 g/dl
before and after TAE, respectively; P = 0.05).
No clinical sign or symptom of ischaemia after TAE
was observed. The mean WBC, LDH, and CPK before
and after TAE were as follows; WBC (μl): 8637 ± 3243,
10212 ± 3490, LDH (IU/l): 275 ± 250, 285 ± 244, CPK
(IU/l): 33 ± 20, 38 ± 30. No significant difference in WBC,Table 2 Haematologic parameters









1 1 7.3 9.1 26 10
2 2 11.3 24 -
3 10.0 0
3 4 9.0 10.5 6 0
5 6.5 8.5 22 8
4 6 8.0 8.2 8 0
7 7.2 8.1 8 0
5 8 7.2 10.7 10 0
6 9 7.4 12 -
10 9.1 10
7 11 9.4 8.7 4 0
Pt. no., patient number; Proc., no., procedure number; Hb, haemoglobin level.
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patient who had two TAE procedures and endoscopies
after each TAE (patient 3), no sign of rebleeding or
ischaemic change was noted.
No death directly relevant to tumour bleeding or
embolisation occurred. Five patients died because of
progression of the original diseases 37 to 247 days
(median: 163 days) after TAE.
Discussion
We experienced no adverse event related to arterial
introduction of IPM/CS, suggesting the safety of IPM/
CS as an embolic material. The 100% technical success
rate indicated the feasibility of TAE using IPM/CS for
bleeding from neoplasms. The effectiveness of TAE
using IPM/CS was suggested by stabilisation of blood
haemoglobin after TAE with a decreased volume of
blood transfusion. Lack of haemorrhagic death further
supports the effectiveness of TAE. Our preliminary expe-
riences indicated that TAE using IPM/CS may contrib-
ute to reduce the blood transfusion.
Proximal embolisation using a gelatin sponge and me-
tallic coil is not recommended because of the possibility
of ischaemic complications (Gordon et al. 1997). In our
series, although IPM/CS was introduced from the prox-
imal site of the artery to cover the tumour staining, no
major ischaemic complication was suggested based on
physical examinations and laboratory data. Although
some previous studies have shown successful embolisa-
tion using PVA introduced from the proximal site for
gastrointestinal bleeding (Defreyne et al. 2001; Loffroy
et al. 2010), the risk of causing an ischaemic event has
been demonstrated in another report (Guy et al. 1992).
Recently, Okuno et al. presented an evaluation of feasi-
bility and effects of TAE using IPM/CS as an embolic
agent to treat tendinopathy and enthesopathy (Okuno
et al. 2013). In this study, IPM/CS with the same con-
centration as our study was introduced from relatively
proximal point of the branches feeding the target site.
Nevertheless, there was no adverse event relating to
IPM/CS embolization. Although, the embolized organs
are different, Okuno’s study may support the safety of
IPM/CS as an embolic agent. The absence of ischaemic
complication after proximal IPM/CS embolisation in our
study was considered due to the transient embolic effect
of IPM/CS, which was demonstrated in our study based
on the findings of recanalisation on repeat TAE.
IPM/CS is an antibiotic agent, and it is slightly soluble
in water. Therefore, IPM/CS ought to dissolve over time.
The transient embolic effect of IPM/CS maybe respon-
sible for rebleeding. Rebleeding occurred in four patients
in the present study. The rebleeding ratio in our study
was higher than that in previous reports using
PVA, glue, a gelatin sponge, and a metallic coil forgastrointestinal bleeding (Defreyne et al. 2001; Guy et al.
1992). However, all repeat TAE procedures after rebleeding
were successful in our series. Because safety should be a
compelling priority in the treatment of chronic tumour
bleeding, transient embolisation with IPM/CS may be
one of the viable therapeutic options if repetition is
acceptable. Additionally, because of the small particle
size of IPM/CS, it would be difficult to stop massive
bleeding using IPM/CS, and its application should be
restricted to the mild, oozing type of bleeding.
A major limitation of our study is the small number of
patients studied.
Another limitation is no proof of macroscopic hemostasis
because the patients did not receive operations or endos-
copy. The superiority of IPM/CS over other embolic
materials as an embolic material for bleeding from neo-
plasms was not evaluated in this study because of the na-
ture of retrospective study. A further study to compare
between IPM/CS and other embolic materials is needed.
In conclusion, our preliminary observations suggest
the feasibility of TAE using IPM/CS as an embolic
material for oozing from the tumour at the duodenum
as well as the small and large intestines. The favourable
result of the present preliminary, retrospective study
warrants a prospective investigation in a larger popula-
tion to determine the safety and effectiveness of TAE
using IPM/CS.
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